Literature DB >> 6166743

Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems.

G R Hanson, L Alphs, W Wolf, R Levine, W Lovenberg.   

Abstract

Protracted blockade of dopamine receptors by haloperidol has been shown to cause a reduction in nigral content of substance P-like immunoreactivity (SPLI). This pharmacological effect is used to study the mechanisms whereby the dopaminergic and substance P systems interact. Data presented in this paper suggest that 1) blockade of dopamine postsynaptic receptors alters nigral SPLI levels associated with the substance P striatal-nigral loop, 2) destruction of the nigral-striatal dopaminergic pathway results in changes in nigral content of SPLI similar to that induced by haloperidol, 3) several weeks after nigral-striatal lesions, compensatory mechanisms mediate a return of nigral SPLI content to control levels and 4) substance P striatal-nigral circuits continue to respond to dopaminergic input after kainic acid lesions in the anterior striatum, whereas properly placed mechanical striatal-nigral lesions appear to be effective in preventing this interaction. The data support a dynamic role for striatal-nigral substance P fibers in the extrapyramidal circuitry and suggest that his pathway must be accounted for when studying the interactions of transmitter systems within this locomotor center.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166743

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.

Authors:  W S Young; T I Bonner; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Control of tachykinin-evoked acetylcholine release from rat striatal slices by dopaminergic neurons.

Authors:  J Alberch; E Arenas; E Pérez-Navarro; J Marsal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

3.  Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies.

Authors:  I Christensson-Nylander; M Herrera-Marschitz; W Staines; T Hökfelt; L Terenius; U Ungerstedt; C Cuello; W H Oertel; M Goldstein
Journal:  Exp Brain Res       Date:  1986       Impact factor: 1.972

4.  Acute reduction of brain substance P induced by nicotine.

Authors:  N E Naftchi; H Maker; E Lapin; J Sleis; A Lajtha; S Leeman
Journal:  Neurochem Res       Date:  1988-04       Impact factor: 3.996

5.  Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug.

Authors:  J A Severson; H E Robinson; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Acute changes in nigral substance P content induced by drugs acting on dopamine, muscarine and GABA receptors.

Authors:  K Koshiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-11       Impact factor: 3.000

Review 7.  Neuropeptides in dopamine-containing regions of the brain.

Authors:  A Albanese; M C Altavista
Journal:  Ital J Neurol Sci       Date:  1984-12

8.  Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor.

Authors:  Duy-Khanh Dang; Eun-Joo Shin; Dae-Joong Kim; Hai-Quyen Tran; Ji Hoon Jeong; Choon-Gon Jang; Seung-Yeol Nah; Jung Hwan Jeong; Jae Kyung Byun; Sung Kwon Ko; Guoying Bing; Jau-Shyong Hong; Hyoung-Chun Kim
Journal:  J Neuroinflammation       Date:  2018-02-21       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.